Fibrocell Science (FCSC) Earning Somewhat Positive News Coverage, Accern Reports

Press coverage about Fibrocell Science (NASDAQ:FCSC) has been trending somewhat positive recently, Accern Sentiment Analysis reports. The research group scores the sentiment of media coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Fibrocell Science earned a media sentiment score of 0.05 on Accern’s scale. Accern also gave news headlines about the company an impact score of 45.2716866653485 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.

FCSC has been the subject of several recent analyst reports. Zacks Investment Research raised shares of Fibrocell Science from a “sell” rating to a “hold” rating in a research note on Tuesday, October 10th. HC Wainwright reaffirmed a “buy” rating and set a $7.60 price objective on shares of Fibrocell Science in a research note on Thursday, October 5th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the stock. The stock presently has an average rating of “Hold” and an average target price of $5.21.

Shares of Fibrocell Science (FCSC) opened at $0.69 on Friday. Fibrocell Science has a 52-week low of $0.61 and a 52-week high of $4.64. The firm has a market capitalization of $15.37, a price-to-earnings ratio of -0.38 and a beta of 0.40.

In other Fibrocell Science news, major shareholder Randal J. Kirk bought 2,727,273 shares of the firm’s stock in a transaction dated Monday, December 11th. The stock was acquired at an average cost of $0.77 per share, for a total transaction of $2,100,000.21. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 2.10% of the stock is currently owned by company insiders.

TRADEMARK VIOLATION NOTICE: “Fibrocell Science (FCSC) Earning Somewhat Positive News Coverage, Accern Reports” was originally reported by StockNewsTimes and is owned by of StockNewsTimes. If you are reading this story on another website, it was illegally copied and republished in violation of US and international trademark & copyright legislation. The correct version of this story can be read at https://stocknewstimes.com/2018/01/12/somewhat-favorable-media-coverage-somewhat-unlikely-to-affect-fibrocell-science-fcsc-stock-price.html.

Fibrocell Science Company Profile

Fibrocell Science, Inc is an autologous cell and gene therapy company. The Company is focused on discovering and developing localized therapies for diseases affecting the skin, connective tissue and joints. Its product candidate, azficel-T, is in development to treat patients suffering from vocal cord scarring that is either idiopathic or age-related.

Insider Buying and Selling by Quarter for Fibrocell Science (NASDAQ:FCSC)

Receive News & Ratings for Fibrocell Science Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fibrocell Science and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply